The internet says a lot. Let’s check the receipt.

The FDA removed BPC-157 from Category 2, and PCAC later recommended 503A Bulks List inclusion for the free base and acetate by 8–6–1 votes. Neither action approved a drug or completed FDA's list-placement process; FDA's final determination remains pending.

A 2025 systematic review screened 544 papers and found one human study: 12 people with chronic knee pain, no control group, and no blinding. It found no human tendon-repair trial.

The injury-healing evidence is preclinical. Human studies discussed in the evidence review involved an eye condition and a leg ulcer, not broad repair of torn tendons, ligaments, or muscles.

There is no pharmacopeial standard defining “TB-500.” The label may refer to full Thymosin Beta-4 or a shorter fragment, and evidence for one substance may not describe the other.

The number comes from a cultured-cell gene-expression analysis, not a clinical trial in living people. A laboratory expression signal is not proof of rejuvenation or a patient benefit.

A disclaimer does not control when the surrounding marketing and context show intended human use. FDA has treated peptide products labeled “Research Use Only” as unapproved drugs after reviewing the claims and products sold with them.

Sharing an ingredient name does not make an online product the FDA-approved drug. FDA warning letters have targeted tirzepatide sold as a research peptide without the approved product's verified manufacturing and labeling framework.

The pivotal efficacy evidence used defined titration and maintenance doses. Randomized evidence has not established that unspecified sub-therapeutic “microdoses” preserve benefits while reducing harms.

Human CJC-1295 research measured growth hormone and IGF-1. It did not demonstrate muscle gain, and PepCurrent found no human trial of the CJC-1295 and ipamorelin combination establishing that outcome.

The original characterization study found no significant ACTH or cortisol increase in swine, even at high experimental doses. That is animal evidence, not proof of the same result or a complete hormone profile in people.

FDA approval belongs to a specific drug product, formulation, manufacturer, and use. Trials of Wegovy, Ozempic, or Rybelsus do not establish the identity, sterility, strength, or performance of an unrelated vial sold under the ingredient name.

Vyleesi is FDA-approved for a narrow population: premenopausal women with acquired, generalized hypoactive sexual desire disorder. Its label says it is not indicated for men, postmenopausal women, or enhancement of sexual performance.

Melanotan II is not FDA-approved. FDA identifies it among substances that may present significant safety risks and describes serious adverse events in the published case record.

Retatrutide now has a published phase 3 diabetes trial. The separate TRIUMPH-1 phase 3 obesity registry is completed but posts no results. It remains investigational and not FDA-approved. Neither record validates an unrelated online product.

EGRIFTA products have a narrow FDA-approved use: reducing excess abdominal fat in adults with HIV and lipodystrophy. The label explicitly says the product is not indicated for weight-loss management.

FDA's evidence review found a lack of support for effectiveness in obesity. The largest identified study enrolled 536 people and found no significant weight-loss difference from placebo at 12 weeks.

Thymosin alpha-1 has human research in specific serious illnesses, but that does not establish a general immune benefit. In a 1,106-person phase 3 sepsis trial, 28-day mortality did not differ significantly from placebo.

A shared ingredient name does not erase differences in reference product, approved indication, labeling, strength, manufacturing controls, or product identity. Large trials establish outcomes for identified products and study conditions, not every vial bearing the word liraglutide.

REDEFINE 1 is a real, large phase 3 trial of coadministered cagrilintide and semaglutide. Novo Nordisk announced an FDA application submission in December 2025, but neither cagrilintide nor CagriSema is an FDA-approved U.S. drug product as of the July 26 review.

CagriSema trials coadministered defined sponsor study products under controlled protocols; the proposed NDA product is a fixed-dose combination. Trial results do not authenticate separately obtained ingredients, an online blend, a compounded product, or a do-it-yourself mixture. CagriSema has been submitted to FDA but is not FDA-approved as of the July 26 review.

A 610-person phase 3 trial in China reported substantial weight loss with identified mazdutide study material. PepCurrent found no FDA-approved mazdutide product, and FDA has cited U.S. online mazdutide products as unapproved new drugs.

FDA granted accelerated approval to Forzinity for improving muscle strength in people with Barth syndrome who weigh at least 30 kg. The pivotal record involved 12 patients with that rare disease and does not establish anti-aging or general wellness benefits.

FDA records document historical Geref products under NDA 19-863 for a diagnostic formulation and NDA 20-443 for a treatment product. Both remain on the discontinued-product list. FDA said they were not withdrawn for safety or effectiveness reasons, but that does not create an anti-aging indication or prove a current product is equivalent to Geref.

Cell and mouse studies report anti-inflammatory signals, but FDA's 2026 review says it identified no KPV clinical studies or human exposure data through any route. Preclinical findings cannot establish a human treatment effect.

Human exercise studies measured the body's own MOTS-c; they did not administer MOTS-c as a treatment. FDA says it did not identify studies administering MOTS-c to humans or human exposure data through any route.

Small human studies measured resting-state brain connectivity after intranasal Semax. They did not establish improved daily function, memory, or productivity, and FDA found the clinical evidence insufficient for the nominated medical uses.

FDA identified one small human biomarker study relevant to circadian-gene expression, not a clinical trial showing age reversal, longer life, or improved patient outcomes. FDA also says it found no clinical human safety studies for Epitalon-related substances.

Small intravenous human studies from the 1980s exist, including a six-person crossover study, but FDA describes the chronic-insomnia evidence as inconclusive and at best preliminary. FDA found no clinical data for the proposed subcutaneous route.